President’s Award

$1000 for most innovative podium presentation selected

from submitted abstracts

Poster Awards

1st place $500

2nd Place $300

3rd Place $200

Deadline for podium abstracts August 16th

Keynote Presentations Aviv Regev (Chair of the Faculty and Core Member, Broad Institute)

“Integrating Cellular and Spatial Maps for a Human Cell Atlas”

Chee-Yeun Chung (Scientific Co-Founder and Director, Yumanity Therapeutics)

“From Yeast to Neurons to Patients: A Novel Drug Discovery Platform for Neu-rodegenerative diseases”

Day 1: Tuesday, September 17th

Educational Courses

The educational program is designed for beginners and experienced users of the technology. The

level of instruction is geared to those new to HCS, but will cover HCS as it is practiced in the real

world, with examples from basic biology and drug discovery. The advanced topics/ elective courses

offer a more in depth review of specific topics related to HCS.

Introductory Session Topics :Image & Data Analysis, High Content Screening methods: work-

stations/robotics, Calibration and Standards

Advanced Session Topics: Machine Learning Methods and Challenges, Phenotypic Assays,

Practical Relationships: Imaging, Phenotypes, Transcriptomics

Colloquium: Cell Painting for Drug Discovery

SBI2 is leading a Cell Painting for Drug Discovery Colloquium, an exciting opportunity for the SBI

2

community to participate in an interactive discussion. This colloquium will address the state of the art

in Cell Painting, including adaptations of imaging and analysis for drug discovery, challenges and

opportunities, and the future of this approach. This session will be conducted by thought leaders in

the field from the Broad Institute and the pharmaceutical industry.

Opening Reception

Educational Program

Time Data Track Assay Development and

Standardization Track Technology Track

Room 214 Room 216 Room 217

9:00-10:00 AM Introduction to image analysis

Basic Concepts in Imaging-Based High-Throughput Screening and High-Throughput Profiling Assay Development

Introduction to flow cytome-

try for microscopists

10:00-10:15 AM Coffee Break

10:15-11:15 AM Data dimensionality reduction:

PCA, t-SNE, UMAP

Introduction to statistics for

HCS/HTS

3D optical microscopy:

methods, techniques, devel-

11:15-11:30 AM Coffee Break

11:30-12:30 PM

Advanced image analysis: fea-

ture extraction, machine learn-

ing

Robust or Go Bust: Guid-

ance Manual : Intro to the Imaging mass spectroscopy

Bray Room Room 216 Room 217

12:30-1:15 PM Hands-On CellProfiler Tutuorial

Grab lunch and head to the

Bray Room for laptop set-up

and CellProfiler Session

Lunch

1:15-2:15 PM HCS of Protein-Protein Inter-

actions

3D cell culture for advanced

High Content Imaging and

2:15-3:00 PM Break

The Education Day lunch and the practical session are sponsored by

Lunchtime Special Presentation by Perkin Elmer

Day 2: Wednesday, September 18th Keynote Session: Aviv Regev

Session 1 HCS High-Throughput Screening successes and learning’s

Debra Nickischer and Regis Doyonnas (Co-Chairs)

High content screening allows us to interrogate simultaneously many cellular parameters representative of the biological activity present in physiologically and disease relevant cell-based assays. By exploring high dimensional phenotypic signatures, complex biological pathways can be mapped so that novel drugs with subtle effects or complex mechanism of actions may finally be identified. The HCS-HTS success and learning session at the 6th Annu-al SBI2 conference will cover success stories and lessons learned when applying these com-plex assays to drug discovery in industry and academia.

Invited Speakers

Kaylene Simpson, Identification of novel factors involved in the nuclear export of mRNA using RNAi and CRISPR-based cellular phenotyping screens, Head, Victorian Centre for Func-tional Genomics ACRF Translational Proteomics – RPPA platform Joshua Harrill, Development and Use of a High Content Imaging-Based Phenotypic Profiling Assay for Bioactivity Screening of Environmental Chemicals, Cellular and Molecular Toxicolo-gist, National Center for Computational Toxicology (NCCT), U.S. Environmental Protection Agency

Alexey Terskikh, Live imaging of epigenetic landscape, Associate Professor, Development Aging and Regeneration Program, Neuroscience and Aging Research Program, Sanford Burn-ham Institute

Session 2 Focus on Imaging in Neurological Disease and Oncology

Le Ai Trinh and Vance Lemmon co-chairs Phenotypic screening is increasingly dependent on modeling, computational approaches and 3D imaging to attack complex biological problems at both high-content and high-throughput. This has been especially empowering in oncology and neuroscience where the use of pluripo-tent stem cells, self-organized organoids and whole animal models are enabling screens for a range of cellular phenotypes from the electrophysiological profile of individual neurons to their degeneration. This session will highlight recent developments that expand our ability to understand the local environment in tumor progression and degeneration and regeneration of the nervous system. Invited Speakers

Shannon Mumenthaler, High content analysis of tumor-CAF crosstalk in colorectal cancer drug response, Associate Professor of Medicine, Lawrence J. Ellison Institute for Transforma-tive Medicine of USC

Graham Dempsey, Scalable Measurements of Intrinsic Excitability in Human iPS Cell-

Derived Excitatory Neurons Using All-Optical Electrophysiology, Senior Vice President of Re-

search and Development, Head of Research and Development, Q-State Biosciences

Daniel Irimia, Dynamic Arrays for Profiling Antitumor Activity of CAR T Cells, Associate Di-

rector, Department of Surgery, Harvard Medical School, Massachusetts General Hospital

SBI2 Annual General Meeting followed by Reception

Keynote Presentation: Chee-Yeun Chung

Day 3: Thursday, September 19th Session 3 Therapeutic Drug Discovery for Complex Disease- How the HCS technologies and other im-

aging modalities support the understanding of complex diseases

George Lee and Daniel Levner co-chairs

Novel technologies such as 3D models and digital pathology are transforming drug develop-

ment through the quality, complexity and human-relevance of the data they produce. In par-

ticular, recent advances in Organ-Chip and organoid technologies have provided new disease

models that more closely recapitulate human disease, while advances in digital pathology

and image analysis allow for the appreciation of spatial relationships within the tissue micro-

environment. In this session we explore these technologies and address their potential to re-

veal mechanisms for therapeutic response.

Invited Speakers

Janna Nawroth

Bonnie Philipps, Phenotyping the tumor micro-environment with advanced tissue-based mul-

tiplexing assays

Lunchtime Special Presentations

Session 4 Machine Learning/Artificial Intelligence and/or Conventional outputs? How to address

which methods for what types of data to make use of all the data

Sam Cooper and Neil Carragher, co-chairs Machine learning has been a feature of drug discovery for almost four decades and

delivered multiple successes, with early algorithms focused around in silico optimiza-

tion of compounds. So what’s all the fuss about now? In contrast to the rules and simulation

based approaches of past decades, new machine learning approaches such as deep-learning

allow us to extract valuable insights from a wide variety of data types, including imaging, se-

quencing, and compound data, without having to explicitly engineer new features for each

data type. In this session we will bring together a group of researchers working on state-of-

the art techniques for microscopy image analysis, and explore how imaging data can be inte-

grated with other data modalities to answer key questions in biological and pharmaceutical

research.

Invited Speakers

David A. Van Valen, Deep learning for single cell biology, Caltech Eric Lubeck, Machine learning: a new approach enabling drug discovery, Insitro